Azitra, Inc. Files for Public Offering

Ticker: AZTR · Form: S-1 · Filed: Apr 28, 2025 · CIK: 1701478

Sentiment: neutral

Topics: ipo, registration-statement, pharmaceutical

TL;DR

Azitra IPO incoming - get ready for a new pharma play.

AI Summary

Azitra, Inc. filed an S-1 registration statement on April 28, 2025, to offer shares to the public. The company, incorporated in Delaware with its principal executive offices in Branford, CT, operates in the pharmaceutical preparations sector. The filing indicates an upcoming public sale of securities, with the exact amount and pricing to be determined.

Why It Matters

This S-1 filing signals Azitra, Inc.'s intention to raise capital through a public offering, which could fund its pharmaceutical development and expansion efforts.

Risk Assessment

Risk Level: medium — As a company pursuing a public offering, Azitra faces typical market risks and the uncertainties inherent in the pharmaceutical industry.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this S-1 filing?

The S-1 filing is a registration statement required by the SEC for companies planning to offer securities to the public, indicating Azitra, Inc.'s intent to conduct an initial public offering (IPO) or a follow-on offering.

When was this S-1 filing submitted?

The S-1 filing was submitted on April 28, 2025.

Where is Azitra, Inc. headquartered?

Azitra, Inc.'s principal executive offices are located at 21 Business Park Drive, Branford, CT 06405.

What is Azitra, Inc.'s Standard Industrial Classification (SIC) code?

Azitra, Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.

Who are the legal representatives mentioned in the filing?

Faith L. Charles, Esq. and Todd Mason, Esq. from Thompson Hine LLP are listed as copies to for legal counsel.

Filing Details

This Form S-1 (Form S-1) was filed with the SEC on April 28, 2025 by Francisco D. Salva regarding Azitra, Inc. (AZTR).

View full filing on EDGAR

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing